Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors | South Carolina Oncology Society

Activity Overview

Desmoid tumors are rare, locally aggressive mesenchymal tumors driven by molecular alterations in the Wnt/APC/β-catenin pathway. Diagnosis remains difficult in community practice, with misdiagnosis occurring in 30%-40% of cases and prolonged diagnostic delays. Many clinicians remain uncertain about molecular workflows, genetic counseling, and how to sequence and manage toxicity from novel therapies.

This program will be delivered as a series of 8 live, CME-certified virtual meetings in collaboration with ACCC-affiliated Oncology State Societies, supported by an enduring online activity. Using an interactive, case-based format tailored to community oncology practice, these virtual meetings include expert presentations on recent data from clinical trials of desmoid tumors, followed by case presentations, discussions, and learner Q&A sessions. The initiative is designed to translate evolving clinical evidence into practical, real-world decision-making and support personalized care for patients with desmoid tumors.

This educational activity is an archive of the live presentation held on September 10, 2026.

Target Audience

This educational program is primarily directed toward community-based oncologists, advanced practice providers, nurses, and other health care professionals involved in the treatment of desmoid tumors.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Apply guideline-based recommendations to overcome diagnostic challenges and ensure accurate identification of desmoid tumors
• Integrate emerging evidence on novel therapies into personalized treatment strategies for patients with desmoid tumors
• Develop multidisciplinary strategies to manage adverse events in patients receiving novel therapies for the treatment of desmoid tumors

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.